Diethyldithiocarbamate
A randomized placebo-controlled multicenter used diethyldithiocarbamate for chemoprotection against CiO in patients with lung or ovarian cancer. Patients who received diethyldithiocarbamate received lower cumulative doses of cisplatin, were more likely to be withdrawn from treatment early due to chemotherapy-related toxicities, and had a trend for a greater reduction in auditory acuity at 3000 Hz (P = 0.095)(Gandara et al., 1995).